Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This article discusses the potential mechanism by which 5α-reductase inhibitors might offer protection against SARS-CoV-2, emphasizing possible roles of dehydroepiandrosterone and its impact on nitric oxide bioavailability, but reports no new experimental results.

This study isolated highly pure oleanolic and maslinic acids from olive milling residues, exploring their chemical reactions, including the formation of finasteride precursors.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

This review discusses the drug repurposing of cardiovascular medications like aspirin and statins for new uses, including potential anti-tumor effects, noting promising experimental outcomes but less conclusive clinical trials, particularly in the field of cancer treatment.

This study used molecular docking to identify stiripentol as a potential new inhibitor of the SRD5A2 enzyme, which is targeted for treating androgen-related diseases; however, in vivo trials are needed to validate its efficacy.

This review discusses various herbal and pharmaceutical products, including their purported uses and possible interactions, but reports no new research findings.

This study reported that the compound (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile effectively stimulated hair growth in mice and reduced sebum production in hamsters.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This case report describes successful treatment with low-dose oral minoxidil for endocrine therapy-induced alopecia in a breast cancer patient unresponsive to topical minoxidil.

This abstract reviews testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production and reports no new research findings.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This study found that inhibiting 5αR1 with dutasteride leads to peripheral insulin resistance and increased body fat in men, which may have implications for its use in treating benign prostatic hyperplasia.

This study found that DHEA along with osteogenic induction medium significantly promotes the osteogenic differentiation and proliferation of human bone marrow mesenchymal stem cells from older individuals.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

In this study, in silico analysis identified Saponin Re and Emodin as promising candidates for topical treatment of androgenetic alopecia, with Biochanin A having the most favorable safety profile among the tested compounds.

In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.

This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

In this study, the combination of Serenoa repens extract with Phenolmicin P3 and Bosexil suppositories significantly improved lower urinary tract symptoms and decreased PSA levels in patients with benign prostatic obstruction-related symptoms.

Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.

3-tetrazolo steroidal analogs can strongly inhibit the enzyme linked to hair loss.